Small, single-center studies suggest that deleterious germline CHEK2 variants may contribute to the development of non-Hodgkin lymphoma (NHL) [19, 20], myeloproliferative neoplasms (MPNs) [21, 22], and myelodysplastic neoplasms (MDS) [23, 24]. Here, CHEK2 is linked to myeloproliferative disorder.